NOTE. Year 2006 used as comparator for descriptive, between-year comparisons. Abbreviation: ESA, erythropoietin-stimulating agent. Year-to-year comparisons for all tumor types were statistically ...
Please provide your email address to receive an email when new articles are posted on . Men with anemia were more likely to have correction of their condition with testosterone therapy vs. placebo.
Over the course of voxelotor treatment, hemoglobin levels and hemolysis markers improved, with results sustained over the treatment period. Adolescents and adults with SCD saw improved hemoglobin ...
Novartis AG NVS released detailed results from the Phase 3 APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with ...
What Are Biomarkers? A Guide to Understanding the Health Indicators Key Takeaways: Biomarkers — aka biological markers — are ...
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare ...
It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier first described a new way to edit genes, called CRISPR, in a scientific paper. The discovery is so game-changing ...
This retrospective longitudinal cohort study used a database of outpatient oncology practice electronic medical records from January 1, 2006, to August 6, 2009. Unit of analysis was episode of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback